Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection Reply

被引：0

作者：

Wefel, Jeffrey S. ^{[1
]}

Noll, Kyle R. ^{[1
]}

Rao, Ganesh ^{[2
]}

Cahill, Daniel P. ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 1515 Holcombe Blvd,Unit 431, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA

来源：

NEURO-ONCOLOGY | 2017年 / 19卷 / 04期

关键词：

D O I：

10.1093/neuonc/now296

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：598 / 599

页数：3

共 50 条

[41] Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma
Tanaka, Kazuhiro
Sasayama, Takashi
Mizukawa, Katsu
Takata, Kumi
Sulaiman, Nor Shazrina
Nishihara, Masamitsu
Kohta, Masaaki
Sasaki, Ryohei
Hirose, Takanori
Itoh, Tomoo
Kohmura, Eiji
CLINICAL NEUROLOGY AND NEUROSURGERY, 2015, 138 : 37 - 44
[42] Highly Sensitive Detection of the IDH1 R132H Mutation in the Plasma of Glioma Patients
Balaj, Leonora
Carter, Bob S.
Castellanos-Rizaldos, Elena
Peruzzi, Pier Paolo
Chan, Dalin
Zhang, Xuan
Skog, Johan
NEUROSURGERY, 2018, 65 : 125 - 126
[43] Automated Machine-Learning Framework Integrating Histopathological and Radiological Information for Predicting IDH1 Mutation Status in Glioma
Wang, Dingqian
Liu, Cuicui
Wang, Xiuying
Liu, Xuejun
Lan, Chuanjin
Zhao, Peng
Cho, William C.
Graeber, Manuel B.
Liu, Yingchao
FRONTIERS IN BIOINFORMATICS, 2021, 1
[44] TERT Promoter Mutation is Associated with Older Age at Diagnosis, Independent of Glioma Grade, Histology and IDH1/2 Status
Pekmezci, Melike
Reis, Gerald
Hansen, Helen
Rice, Terri
Zheng, Shichun
Wiencke, John
Perry, Arie
Wrensch, Margaret
Walsh, Kyle
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2014, 73 (06): : 586 - 587
[45] Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection
Noll, Kyle R.
Sullaway, Catherine
Ziu, Mateo
Weinberg, Jeffrey S.
Wefel, Jeffrey S.
NEURO-ONCOLOGY, 2015, 17 (04) : 580 - 587
[46] In response: IDH1 mutation expression is associated with seizures and protoplasmic subtype in patients with low-grade glioma
Morokoff, Andrew
Liubinas, Simon
EPILEPSIA, 2014, 55 (10) : 1679 - 1680
[47] IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients
Crucitta, Stefania
Pasqualetti, Francesco
Gonnelli, Alessandra
Ruglioni, Martina
Luculli, Giovanna Irene
Cantarella, Martina
Ortenzi, Valerio
Scatena, Cristian
Paiar, Fabiola
Naccarato, Antonio Giuseppe
Danesi, Romano
Del Re, Marzia
BMC CANCER, 2024, 24 (01)
[48] IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients
Stefania Crucitta
Francesco Pasqualetti
Alessandra Gonnelli
Martina Ruglioni
Giovanna Irene Luculli
Martina Cantarella
Valerio Ortenzi
Cristian Scatena
Fabiola Paiar
Antonio Giuseppe Naccarato
Romano Danesi
Marzia Del Re
BMC Cancer, 24
[49] Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML
Stone, Richard M.
Choe, Sung
Zhang, Vickie
Marteyn, Benoit
Penard-Lacronique, Virginie
Wang, Hongfang
DiNardo, Courtney D.
Stein, Eytan M.
Fathi, Amir T.
Tallman, Martin S.
Kantarjian, Hagop M.
Attar, Eyal C.
Wu, Bin
de Botton, Stephane
BLOOD, 2017, 130
[50] IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma
Zeng, Ailiang
Hu, Qi
Liu, Yanwei
Wang, Zheng
Cui, Xiaoming
Li, Rui
Yan, Wei
You, Yongping
ONCOTARGET, 2015, 6 (30) : 30232 - 30238

← 1 2 3 4 5 →